Research ArticleCare of hepatitis C virus infection in human immunodeficiency virus-infected patients: Modifications in three consecutive large surveys between 2004 and 2009

Background & AimsTo analyze the care of HCV infection in HIV-HCV coinfected patients and its progression between 2004 and 2009.MethodsThree hundred eighty HIV-HCV coinfected patients were prospectively included from November 22 to 29, 2004 (2004 survey), 416 patients from April 3 to 10, 2006 (2006 survey), and 419 patients from June 15 to 22, 2009 (2009 survey).ResultsThe rate of liver biopsy decreased (14% vs. 38% vs. 56%), while the use of non-invasive liver damage tests increased (47% vs. 24% vs. ND) in the 2009, 2006, and 2004 surveys, respectively. The rate of patients that had never been treated for HCV infection progressively decreased in the 2009, 2006, and 2004 surveys (37%, 42%, and 54%). The main reasons for HCV non-treatment changed as HCV treatment was deemed less questionable and the lack of liver biopsy became a very rare reason (6%, 18%, and 34%). Among patients treated for HCV infection, the rate of sustained virological response increased (49%, 29%, and 29%). The main factors independently associated with HCV treatment were a liver fibrosis score ⩾F2 (odds ratio = 3.5; 95% CI 2.1-5.7), a liver biopsy activity grade ⩾A2 (2.7; 1.4-5.3), a CD4 cell count ⩾350 ml (2.7; 1.6-4.4), European origin (2.1; 1.3-3.4), daily alcohol consumption < 30 g (2.1; 1.2-3.8), and male gender (2.0; 1.2-3.3).ConclusionCompared to the 2004 and 2006 surveys, the 2009 coinfected patients had liver damage assessment more frequently, more patients had received HCV treatment and more patients had achieved a sustained virological response.